November 22, 2019
Article
Clinical Articles
Building upon the initial successes of anti–PD-1 and anti–CTLA-4 therapies has been a major focus of drug development over the past several years—basically, in search of other agents that could generate “immune-synergy.” What the term means and implies is critically important: It refers to drugs that work better together than alone (or in sequence) through their individual mechanisms of action to enhance the host immune-response to cancer.
November 20, 2019
Article
Clinical Articles
Given the frequency of FGFR2 alterations in intrahepatic cholangiocarcinoma, investigators have identified it as a potential prognostic indicator of survival and a rational target of systemic cancer therapies.
November 19, 2019
Article
Clinical Articles
The early development of PARP inhibitors in 2003 focused on their use in combination with cytotoxic chemotherapy agents, but this was eventually abandoned because of excess toxicity.
November 18, 2019
Article
Clinical Articles
Precision medicine has afforded oncologists the opportunity to develop individualized approaches to treat non–small cell lung cancer, one of the most devastating malignant disorders, which until the past decade was thought to be invariably fatal within months.